Dec 6 (Reuters) - BIOAGE Labs Inc BIOA.O:
BIOAGE LABS ANNOUNCES DISCONTINUATION OF STRIDES PHASE 2 CLINICAL TRIAL EVALUATING AZELAPRAG IN COMBINATION WITH TIRZEPATIDE FOR THE TREATMENT OF OBESITY
BIOAGE LABS INC - NO TRANSAMINASE ELEVATIONS IN TIRZEPATIDE ONLY GROUP
BIOAGE LABS INC - DECISION FOLLOWS OBSERVATIONS OF LIVER TRANSAMINITIS WITHOUT CLINICALLY SIGNIFICANT SYMPTOMS IN SOME SUBJECTS ON AZELAPRAG
BIOAGE LABS INC - DOSING DISCONTINUED, NO ADDITIONAL SUBJECTS TO BE ENROLLED
Source text: ID:nGNX5JjjwD
Further company coverage: BIOA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.